FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W96277209> ?p ?o ?g. }

• W96277209 abstract "America’s biotechnology industry is the envy of the world. No other country hosts more, bigger, and more innovative biotechnology firms than the United States. Since the late 1970s, a range of federal policies have stimulated the supply-side for these technologies. Mostly unnoticed – until recently, however – has been the impact of the demand side for the comparative advantage that America’s biotechnology industry enjoys: A fragmented healthcare system without an overarching federal drug pricing authority. As a consequence, Americans spend more on prescription drugs than citizens in any other country of the world. In particular, the most recent, most advanced biotechnology-based medicines that could easily run costs of tens of thousands of dollars annually have exacerbated the tension in America’s healthcare system: High prices are seen by some as too exclusionary, but for others they are the industry’s raison d’etre. This paper will present the access to biotechnology drugs as a case study of how America’s market-based healthcare system mediates between conflicting rights: It allows studying how individual behavior, products, corporate practices, and budgetary constraints contradict the rights of other parties. Should it, for instance, be left to the market alone to determine that an investor in biotechnology has a right to recoup a higher profit than from investing in other assets, for instance real estate? These are ultimately political decisions. Against this backdrop, the proposed paper scrutinizes the politics and the interest group representation of the biotechnology industry during President Obama’s healthcare reform. Unlike in the 1990s when the industry flatly opposed President Clinton’s healthcare overhaul, this time biotechnology firms and their interest group representatives pursued a more conciliatory, flexible lobbying strategy. As a consequence, the Patient Protection and Affordable Care Act, passed by Congress and signed into law by the President in March 2010, includes a number of giveaways to the industry. If implemented, the Act would for example perpetuate the lack of an overarching governmental mechanism for price control for drugs. But would this move the burden of cost control to private insurance companies and what would this imply for the biotechnology industry? This paper will discuss these and other implications of Obamacare for the innovation model of the biotechnology industry on the one hand and the right of patients to access the most advanced technologies on the other." @default.
• W96277209 created "2016-06-24" @default.
• W96277209 creator A5011462495 @default.
• W96277209 date "2011-01-01" @default.
• W96277209 modified "2023-10-03" @default.
• W96277209 title "A Shot in the Arm? Implications of Obamacare for the Biotechnology Industry" @default.
• W96277209 cites W2001502598 @default.
• W96277209 cites W2031104099 @default.
• W96277209 cites W2224948436 @default.
• W96277209 cites W2802019512 @default.
• W96277209 cites W621977033 @default.
• W96277209 cites W656952922 @default.
• W96277209 hasPublicationYear "2011" @default.
• W96277209 type Work @default.
• W96277209 sameAs 96277209 @default.
• W96277209 citedByCount "0" @default.
• W96277209 crossrefType "posted-content" @default.
• W96277209 hasAuthorship W96277209A5011462495 @default.
• W96277209 hasConcept C144133560 @default.
• W96277209 hasConcept C150903083 @default.
• W96277209 hasConcept C160735492 @default.
• W96277209 hasConcept C162324750 @default.
• W96277209 hasConcept C175444787 @default.
• W96277209 hasConcept C17744445 @default.
• W96277209 hasConcept C181622380 @default.
• W96277209 hasConcept C199539241 @default.
• W96277209 hasConcept C2779652045 @default.
• W96277209 hasConcept C50522688 @default.
• W96277209 hasConcept C86803240 @default.
• W96277209 hasConcept C94625758 @default.
• W96277209 hasConceptScore W96277209C144133560 @default.
• W96277209 hasConceptScore W96277209C150903083 @default.
• W96277209 hasConceptScore W96277209C160735492 @default.
• W96277209 hasConceptScore W96277209C162324750 @default.
• W96277209 hasConceptScore W96277209C175444787 @default.
• W96277209 hasConceptScore W96277209C17744445 @default.
• W96277209 hasConceptScore W96277209C181622380 @default.
• W96277209 hasConceptScore W96277209C199539241 @default.
• W96277209 hasConceptScore W96277209C2779652045 @default.
• W96277209 hasConceptScore W96277209C50522688 @default.
• W96277209 hasConceptScore W96277209C86803240 @default.
• W96277209 hasConceptScore W96277209C94625758 @default.
• W96277209 hasLocation W962772091 @default.
• W96277209 hasOpenAccess W96277209 @default.
• W96277209 hasPrimaryLocation W962772091 @default.
• W96277209 hasRelatedWork W1522428479 @default.
• W96277209 hasRelatedWork W1604049451 @default.
• W96277209 hasRelatedWork W1971282191 @default.
• W96277209 hasRelatedWork W1986921909 @default.
• W96277209 hasRelatedWork W2068927803 @default.
• W96277209 hasRelatedWork W2266068650 @default.
• W96277209 hasRelatedWork W227314823 @default.
• W96277209 hasRelatedWork W2475822445 @default.
• W96277209 hasRelatedWork W2492249003 @default.
• W96277209 hasRelatedWork W2498203428 @default.
• W96277209 hasRelatedWork W256292320 @default.
• W96277209 hasRelatedWork W259295880 @default.
• W96277209 hasRelatedWork W2750063544 @default.
• W96277209 hasRelatedWork W276453217 @default.
• W96277209 hasRelatedWork W2947245480 @default.
• W96277209 hasRelatedWork W3122904077 @default.
• W96277209 hasRelatedWork W3123355245 @default.
• W96277209 hasRelatedWork W3164190330 @default.
• W96277209 hasRelatedWork W176419767 @default.
• W96277209 hasRelatedWork W230748389 @default.
• W96277209 isParatext "false" @default.
• W96277209 isRetracted "false" @default.
• W96277209 magId "96277209" @default.
• W96277209 workType "article" @default.